Epidarex Capital is a transatlantic venture capital firm that invests in early-stage, high-growth life science and health technology companies in under-ventured research hubs across the UK and US. The firm focuses on company creation, often sourcing and building therapeutics and medical device companies from scratch.
38% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (44% of deals). Average disclosed round size is $23.8M (across 18 rounds with reported amounts).
Portfolio
22
Fund Size
—
Top Stage
Series A
Last 12 Mo
3
Team
A. Sinclair Dunlop
Managing Partner
BH
Bridget Harris
Director of Operations
SM
Sara McGeachy
Investor Relations Analyst
AP
Andrew Prince
Staff Accountant
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
32 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Mironid | Series B | $46M | Aug 2026 |
| RRapidPulse, Inc. | Series B | $48M | Jul 2026 |
| RRapidPulse, Inc. | Series B | $48M | Jan 2026 |
| EEpsilogen Ltd | Series B | — | Sep 2024 |
 Curve Therapeutics | Series A | $51.4M | Feb 2024 |
 Enterprise Therapeutics | Series B | $26M | Jan 2024 |
| Mironid | Series A | — | Sep 2023 |
| TTransine Therapeutics | Seed | $5.8M | May 2022 |
 Leucid Bio | Series A | $15.5M | Oct 2021 |
 Topas Therapeutics | Series B | — | Jul 2021 |
 Slate Bio, Inc. | Seed | $1.8M | Jan 2021 |
 Libra Therapeutics | Series A | $29M | Sep 2020 |
 Nodthera | Series B | $55M | Jun 2020 |
| EEpsilogen Ltd | Series A | — | Apr 2020 |
| AAdoRx Therapeutics | Unknown | $10M | Nov 2018 |
| AAdoRx Therapeutics | Unknown | $10M | Jun 2018 |
| AAdoRx Therapeutics | Unknown | $10M | Jan 2018 |
| Topas Therapeutics | Series A | — | Jan 2016 |
| CConfluence Life Sciences | Series A | $2.4M | Jun 2015 |
| Enterprise Therapeutics | Series A | — | Jan 2015 |
| HHarpoon Medical, Inc. | Series A | $3.2M | Jan 2015 |
| SSIRAKOSS | Series A | $3.1M | Dec 2014 |
| HHarpoon Medical, Inc. | Series A | $3.8M | Sep 2014 |
| EEdinburgh Molecular Imaging | Series A | — | Feb 2014 |
| Enterprise Therapeutics | Seed | — | Jan 2014 |
Page 1 of 2
Top Co-Investors
Sofinnova Partners5 shared
Scottish Investment Bank4 shared
British Business Bank3 shared
Versant Ventures3 shared
Dementia Discovery Fund2 shared
British Patient Capital2 shared
Roche Venture Fund2 shared
BioGeneration Ventures2 shared
Gimv2 shared
F-Prime Capital2 shared
Medtronic2 shared
S3 Ventures2 shared
Florida Opportunity Fund2 shared
SBI Investment2 shared
Maryland Venture Fund2 shared
EQT Life Sciences1 shared
Pfizer Ventures1 shared
Columbus Venture Partners1 shared
Last updated: 8 September 2026